Table 2.
Baseline clinical characteristics and assessments
| Characteristic | Overall N = 508 |
Tape measurement N = 245 |
BIS N = 263 |
p value |
|---|---|---|---|---|
| Medicationsa | ||||
| β-Blockers | 40 (8.0) [500] | 19 (7.9) [241] | 21 (8.1) [259] | 0.926 |
| Diuretics | 59 (11.7) [506] | 23 (9.4) [245] | 36 (13.8) [261] | 0.123 |
| Oral steroids | 12 (2.4) [505] | 5 (2.0) [244] | 7 (2.7) [261] | 0.641 |
| NSAIDs | 116 (22.9) [506] | 48 (19.6) [245] | 68 (26.1) [261] | 0.084 |
| Most commonly reported history of comorbid conditionsa,b | ||||
| Cardiovascular | 223 (44.0) [507] | 106 (43.3) [245] | 117 (44.7) [262] | 0.752 |
| Skeletal | 165 (32.5) [507] | 80 (32.7) [245] | 85 (32.4) [262] | 0.960 |
| Endocrine | 123 (24.3) [507] | 53 (21.6) [245] | 70 (26.7) [262] | 0.182 |
| Digestive | 119 (23.5) [507] | 71 (29.0) [245] | 48 (18.3) [262] | 0.005 |
| Integumentary | 107 (21.1) [507] | 52 (21.2) [245] | 55 (21.0) [262] | 0.949 |
| History of surgerya,b | ||||
| Any | 437 (86.2) [507] | 208 (84.9) [245] | 229 (87.4) [262] | 0.414 |
| Arm | 36 (8.4) [431] | 14 (6.9) [204] | 22 (9.7) [227] | 0.289 |
| Shoulder | 17 (3.9) [431] | 7 (3.4) [204] | 10 (4.4) [227] | 0.604 |
| Truncal | 85 (19.7) [432] | 44 (21.5) [205] | 41 (18.1) [227] | 0.374 |
| Stage of cancera | 0.227 | |||
| 0 (DCIS) | 22 (4.3) | 12 (4.9) | 10 (3.8) | |
| I | 288 (56.7) | 129 (52.7) | 159 (60.5) | |
| II | 164 (32.3) | 89 (36.3) | 75 (28.5) | |
| III | 34 (6.7) | 15 (6.1) | 19 (7.2) | |
| Baseline assessmentsc | ||||
| BIS | 0.0 [−3 to 3] (508) | −0.1 [−3 to 3] (245) | 0.0 [−3 to 3] (263) | 0.959 |
| Arm volume | ||||
| At-risk arm, mL | 1943.2 [1685–2344] (508) | 1929.4 [1686–2360] (245) | 1971.6 [1682–2323] (263) | 0.533 |
| Non-at-risk arm, mL | 1949.6 [1667–2335] (508) | 1947.5 [1668–2334] (245) | 1958.2 [1667–2337] (263) | 0.698 |
| Percentage difference | 0.2 [−2 to 4] (508) | 0.4 [−2 to 3] (245) | 0.2 [−3 to 4] (263) | 0.629 |
| BMI | 27.9 [24−33] (507) | 28.3 [24–33] (244) | 27.9 [24–33] (263) | 0.809 |
| Number of skin conditions | ||||
| At-risk arm | 0.0 [0–1] (508) | 0.0 [0–1] (245) | 0.0 [0–1] (263) | 0.911 |
| Non-at-risk arm | 0.0 [0–1] (507) | 0.0 [0–1] (244) | 0.0 [0–1] (263) | 0.901 |
Bold value indicates statistical significance (p < 0.05)
NSAIDs non-steroidal anti-inflammatory drugs, BIS bioimpedance spectroscopy, DCIS ductal carcinoma in situ, BMI body mass index, IQR interquartile range
aData are expressed as N yes (% yes) [N responses]
bBesides current breast cancer
cData are expressed as median [IQR] (N)